Therapeutic index of lymphadenectomy among patients with pancreatic neuroendocrine tumors: A multi‐institutional analysis by Wu, Lu et al.
J Surg Oncol. 2019;120:1080–1086.wileyonlinelibrary.com/journal/jso1080 | © 2019 Wiley Periodicals, Inc.
Received: 5 August 2019 | Accepted: 16 August 2019
DOI: 10.1002/jso.25689
R E S EARCH AR T I C L E
Therapeutic index of lymphadenectomy among patients with
pancreatic neuroendocrine tumors: A multi‐institutional
analysis
Lu Wu MD1,2 | Kota Sahara MD2,3 | Diamantis I. Tsilimigras MD2 |
Shishir K. Maithel MD4 | George A. Poultsides MD5 | Flavio G. Rocha MD6 |
Sharon M. Weber MD7 | Ryan C. Fields MD8 | Kamran Idrees MD9 |
Clifford S. Cho MD10 | Feng Shen MD1 | Timothy M. Pawlik MD, MPH, PhD, FACS2 |
and other members of the U.S. Neuroendocrine Tumor Study Group
1Department of Hepatic Surgery, Eastern
Hepatobiliary Surgery Hospital, Shanghai, China
2Department of Surgery, Division of Surgical
Oncology, The Ohio State University Wexner
Medical Center, Columbus, Ohio
3Department of Gastroenterological Surgery,
Yokohama City University School of Medicine,
Yokohama, Japan
4Department of Surgery, Emory University,
Atlanta, GA
5Department of Surgery, Stanford University,
Stanford, CA
6Department of Surgery, Virginia Mason
Medical Center, Seattle, Washington
7Department of Surgery, University of
Wisconsin School of Medicine and Public
Health, Madison, Wisconsin
8Department of Surgery, Washington University
School of Medicine, St. Louis, Missouri
9Division of Surgical Oncology, Department of
Surgery, Vanderbilt University, Nashville,
Tennessee
10Division of Hepatopancreatobiliary and
Advanced Gastrointestinal Surgery,
Department of Surgery, University of
Michigan, Ann Arbor, Michigan
Correspondence
Timothy M. Pawlik, MD, MPH, PhD, FACS,
FRACS (Hon), Division of Surgical Oncology,
Department of Surgery, James Comprehensive
Cancer Center, Wexner Medical Center, The
Ohio State University, 395 W 12th Ave, Suite
670, Columbus, OH 43210.
Email: Tim.Pawlik@osumc.edu
Abstract
Background: The benefit derived from lymph node dissection (LND) in patients with
pancreatic neuroendocrine tumors (pNETs) based on clinicopathological character-
istics remains unclear.
Methods: Patients undergoing surgery for pNET between 1997 and 2016 were
identified using a multi‐institutional dataset. The therapeutic index of LND relative to
patient characteristics was calculated.
Results: Among 647 patients, the median number of lymph nodes (LNs) evaluated
was 10 (interquartile range: 4‐16) and approximately one quarter of patients had
lymph node metastasis (LNM) (N = 159, 24.6%). Among patients with LNM, 5‐year
recurrence‐free survival was 56.0%, reflecting a therapeutic index value of 13.8. The
therapeutic index was highest among patients with a moderately/poorly‐differen-
tiated pNET (21.5), Ki‐67 ≥ 3% (20.1), tumor size ≥2.0 cm (20.0), and tumor location at
the head of the pancreas (20.0). Patients with ≥8 LNs evaluated had a higher
therapeutic index than patients who had 1 to 7 LNs evaluated (≥8: 17.9 vs 1‐7: 7.5;
difference of index: 11.4).
Conclusion: LND was mostly beneficial among patients with pNETs >2 cm, Ki‐
67 ≥ 3%, and lesions located at the pancreatic head as identification of LNM was most
common among individuals with these tumor characteristics. Evaluation of ≥8 LNs
was associated with a higher likelihood of identifying LNM as well as a higher
therapeutic index, and therefore this number of LNs should be considered the goal.
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1 | INTRODUCTION
Pancreatic neuroendocrine tumors (pNETs) are rare neoplasms of the
gastrointestinal tract with a rising incidence in the United States.1,2
Resection is the mainstay of treatment among patients with
resectable pNETs although several nonsurgical techniques have been
employed.3-5 While lymphadenectomy is typically performed at the
time of resection to stage the disease, the role of routine lymph node
dissection (LND) and the associated oncological therapeutic benefit
remain controversial.4 For example, while data from a single‐
institution cohort of 136 patients with pNET reported that lymph
node metastasis (LNM) was associated with shorter disease‐free
survival (DFS),6 a separate population‐based study of 3851 patients
demonstrated that nodal status was not necessarily associated with
overall survival (OS).7 In light of these data, several investigators
have questioned the benefit of routine LND in the treatment of
patients with nonfunctional pNET and a Ki‐67 < 3%.8 In fact, one
recent study noted that patients who had a pNET ≤2.0 cm and a Ki‐
67 < 3% in the distal pancreas had an incidence of LNM as low as
3.4% and, therefore, questioned the need for routine LND.9
While many studies support the predictive role of LNM and
therefore the role of LND, robust evidence is lacking to support an
actual therapeutic benefit for routine LND in pNET patients with
resectable disease.4 To this end, Sasako et al10 have suggested using
the “therapeutic index” as a means to determine any potential
survival benefit associated with LND among patients undergoing
surgical resection. The rationale of the therapeutic index is to
identify patients who are most likely to have LNM and, therefore,
derive a benefit from LND.10 The therapeutic index concept has been
examined and validated for several other cancers including gastric,
colorectal, cholangiocarcinoma, and lung.10-14 Nevertheless, to date,
no study has assessed the therapeutic value of LND among patients
with pNETs. As such, the objective of the current study was to define
the therapeutic index of LND among patients undergoing resection of
pNETs. In particular, we sought to identify preoperative patient
factors, as well as clinicopathologic features of pNETs, that were
associated with the potential clinically relevant therapeutic benefit
associated with LND.
2 | METHODS
2.1 | Study population and data collection
Patients who underwent pancreatectomy for pNETs between 1997
and 2016 were identified using a multi‐institutional database from
eight tertiary institutions (The Ohio State University Comprehensive
Cancer Center, Columbus, OH; University of Michigan, Ann Arbor,
MI; Stanford University, Palo Alto, CA; Virginia Mason Medical
Center, Seattle, WA; Winship Cancer Institute, Emory University,
Atlanta, GA; Washington University, School of Medicine, St Louis,
MO; University of Wisconsin, School of Medicine and Public Health,
Madison, WI; Vanderbilt University, Nashville, TN).15 All patients
included in the study had a histologically proven pNET and
underwent a curative intent pancreatectomy along with LND.
Patients with metastatic disease, as well as individuals with
macroscopically positive surgical margins (R2 resection), missing
follow‐up data, and individuals who died within 30 days of surgery
were excluded from the analysis. The study was approved by the
Institutional Review Board of all participating institutions.
Patient demographics and clinicopathologic data included age,
sex, race, American Society of Anesthesiologist (ASA) class, func-
tional status, type of resection, tumor size, tumor location, tumor
number, number of lymph nodes (LNs) examined, number of LNM,
tumor grade, resection margin status, Ki‐67 status, presence of
lymphovascular or perineural invasion, and receipt of adjuvant
therapy. Functional tumors were defined as lesions with hormone
overproduction (ie, insulinoma, gastrinoma, somatostatinoma, and
VIPoma).16 LND was defined as the removal of LNs from regional
nodal stations. All resected specimens were submitted for histo-
pathologic analysis by an experienced pathologist at each institution.
2.2 | Calculation of the therapeutic index
The frequency of LNM was calculated by dividing the number of
patients with LNM in a particular group by the total number of
patients in that subgroup.14 The therapeutic index of LND was
calculated by multiplying the frequency of LNM in a particular group
by the 5‐year recurrence‐free survival (RFS) rate of patients with
LNM in that specific subgroup of patients, as previously reported17;
the 5‐year endpoint was based on previous studies.11,18,19 Similar to
previous reports, a therapeutic index difference of more than 10 was
considered meaningful.14,17,18
2.3 | Statistical analysis
Continuous and categorical variables were presented as median
(interquartile range [IQR]) and frequency (%), respectively. Logistic
regression was utilized to detect independent predictors of LNM.
RFS was defined as the time duration from the date of surgery to
tumor recurrence. Recurrence was defined as identification of
suspicious imaging findings or biopsy‐proven tumor. OS was
calculated from the date of surgery to date of death or last follow‐
up. Survival curves were estimated using the Kaplan‐Meier method
and differences between curves were investigated with the logrank
test. Statistical significance was assessed at α = .05. All statistical
analyses were performed using SPSS, version 25 (IBM Corp, Armonk,
NY).
3 | RESULTS
3.1 | Characteristics of patients undergoing
lymphadenectomy
Among 1125 patients who underwent curative‐intent resection of
pNETs, 647 (57.5%) patients underwent LND and were included in
the final analysis (Table 1). Median patient age at the time of surgery
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was 58 years old (IQR: 48‐66); roughly one‐half of patients were male
(N = 343, 53.0%) and had an ASA score of 3 (N = 328, 52.6%). Most
patients were white (N = 480, 80.7%), had a nonfunctional tumor
(N = 559, 88.0%) and a tumor located in the body or tail of the
pancreas (N = 385, 59.6%), and underwent a distal pancreatectomy
(N = 392, 60.6%) through an open surgical approach (N = 491, 75.9%).
Most patients had unifocal disease (N = 590, 92.0%) and median
tumor size of 2.2 cm (IQR: 1.4‐3.8). The median number of LNs
evaluated was 10 (IQR: 4‐16) and approximately one‐quarter of
patients had LNM (N = 159, 24.6%). Most patients underwent an R0
resection (N = 537, 83.8%) (Table 1).
3.2 | Preoperative factors associated with LNM
On bivariate analysis, male sex (odds ratio [OR], 1.54, 95%
confidence interval [CI], 1.07‐2.22), functional pNET status (OR,
0.48; 95% CI, 0.25‐0.94), symptomatic pNET (OR, 1.53; 95% CI, 1.05‐
2.23), primary location of tumor in the head of pancreas (OR, 2.41;
95% CI, 1.67‐3.47), tumor size ≥2.0 cm (OR, 5.90; 95% CI, 3.78‐9.21),
number of LNs evaluated ≥8 (OR, 3.04; 95% CI, 1.99‐4.64),
moderately (OR, 2.78; 95% CI, 1.62‐4.79) or poorly differentiated
(OR, 6.67; 95% CI, 2.19‐20.33) tumors, and Ki‐67 between 3% and
20% (OR, 3.34; 95% CI, 2.11‐5.30), or Ki‐67 > 20% (OR, 7.84; 95% CI,
2.97‐20.69) were associated with LNM. On multivariable analysis,
only the presence of symptoms (OR, 2.03; 95% CI, 1.17‐3.51),
primary tumor in head of pancreas (OR, 1.83; 95% CI, 1.10‐3.06),
tumor size ≥2.0 cm (OR, 4.59; 95% CI, 2.57‐8.20), and Ki‐67 between
3% and 20% (OR, 1.83; 95% CI, 1.04‐3.22) remained associated with
a higher likelihood of LNM (Table 2).
3.3 | Survival and therapeutic index by
preoperative factors
After a median follow‐up of 33.9 months (IQR: 11.9‐62.6), 5‐year OS
was 84.1% (95% CI, 74.9‐90.3) among patients with LNM vs 93.8%
TABLE 1 Demographic and patient characteristics in the entire
cohort (n = 647)
Variable N (%)























Classic PD 76 (11.7%)
Pylorus‐preserving PD 129 (19.9%)
Central pancreatectomy 10 (1.5%)
Distal pancreatectomy 392 (60.6%)











Presence of LN metastasis 159 (24.6%)
Number of LN examined, median (IQR) 10 (4‐16)






Moderately differentiated 63 (10.9%)

















Abbreviations: ASA, American Society of Anesthesiologist; IQR, inter-
quartile range; LN, lymph node; MIS, minimally invasive surgery; PD,
pancreatoduodenectomy .
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(95% CI, 90.1‐96.1) among patients with negative LNs (P < .001;
Figure 1A). Similarly, 5‐year RFS was 56.0% (95% CI, 44.7‐66.7) vs
83.3% (95% CI, 77.9‐87.6) among patients who did and did not have
LNM, respectively (P < .001; Figure 1B).
Irrespective of other factors, patients with poor to undifferen-
tiated tumor grade had the worst 5‐year RFS (46.0%) followed by
symptomatic patients (49.3%) (Table 3). The highest therapeutic
value of lymphadenectomy was noted among patients with moder-
ately to poorly differentiated tumor grade (21.5), Ki‐67 ≥ 3% (20.1),
tumor size ≥2.0 cm (20.0), and primary tumor location in the head of
the pancreas (20.0). An index difference of more than 10 points was
noted when examining tumor size (index difference: 13.4; <2.0: 6.6 vs
≥2.0: 20.0), Ki‐67 (index difference: 12.6; <3%: 7.5 vs ≥3%: 20.1),
location of tumor (index difference: 10.3; body/tail: 9.7 vs head: 20.0)
as well as the number of LNs evaluated (index difference: 10.4; 1‐7:
7.5 vs ≥8: 17.9) (Table 3). Of note, patients who had ≥8 LNs evaluated
had a higher therapeutic index than patients who had 1 to 7 LNs
evaluated (≥8: 17.9 vs 1‐7: 7.5; difference of index: 11.4).
4 | DISCUSSION
The prognostic impact of LNM and the therapeutic role of LND to
remove LNM among patients with pNETs remain a topic of debate.
Several studies have reported that LNM was not associated with OS
among patients undergoing resection of pNET.7,20 While several other
studies reported that the presence of LNM was associated with worse
RFS,6,21,22 other investigators have noted that 5‐ and 10‐year OS were
comparable among patients who did and did not have LNM.6,22 As
such, the therapeutic value of routine LND still remains controversial
among patients undergoing surgery for pNETs, despite the possibility
that removal of LNM may decrease locoregional recurrence.4 The
current study was important because we identified patients who may
have the most benefit from LND by calculating the therapeutic index
on the basis of clinicopathological characteristics.10 Of note, a
difference in the therapeutic index above 10 was identified among
patients who had a tumor size larger than 2 cm (≥2: 20.0 vs <2: 6.6;
difference of index: 13.4), patients who had a Ki‐67 ≥ 3% (≥3%: 20.1 vs
<3%; difference of index: 12.6), as well as patients with a pNET located
in the head of the pancreas (head: 20.0 vs body/tail: 9.7; difference of
index: 10.3). Of note, the therapeutic index was also associated with
the total number of nodes evaluated as patients who had ≥8 LNs
evaluated had a higher therapeutic index than patients who had 1 to 7
LNs evaluated. To the best of our knowledge, this is the first study to
examine the therapeutic benefit associated with LND among patients
who underwent a curative‐intent resection for a pNET.
First proposed by Sasako et al,10 the therapeutic index has been
used in assessing the role of LND in the surgical management of
gastric, rectal,11 esophageal,12 and lung cancer.13 In addition, our
own group recently examined the therapeutic benefit associated with
LND among patients with intrahepatic cholangiocarcinoma and
identified particular groups of patients who were most likely to
derive a benefit from LND.14,23 The rationale of the therapeutic index
is that the utilization of LND would be most effective when it is
employed among patients who have the highest risk for LNM and
therefore have the greatest chance of a therapeutic benefit.10 Given
the conflicting results about the role of LND for patients undergoing
surgery for pNET, the therapeutic index could be a relevant way to
identify which specific subgroups of patients may particularly
warrant LND.10 Indeed, the goal of LN harvesting may not only be
the accurate staging, but also could act as a means to reduce
locoregional disease among patients with LNM. To this end, the
current study noted that certain clinicopathological characteristics
were associated with a reasonable therapeutic index difference,
including primary tumor location, tumor size, Ki‐67, and number of
LNs evaluated (Table 3). Of note, while 5‐year RFS was not different
among these groups of patients, the higher rates of LNM in each
particular subgroup of patients (ie, patients with tumor located at the
TABLE 2 Logistic regression analysis of clinicopathological factors





OR 95% CI OR 95% CI
Age
<65 Ref – – –
≥65 0.95 0.63‐1.42 – –
Sex
Female Ref – Ref –
Male 1.54 1.07‐2.22 1.50 0.90‐2.52
Functional status
Nonfunctional Ref – Ref –
Functional 0.48 0.25‐0.94 0.43 0.17‐1.07
Symptomatic
No Ref – Ref –
Yes 1.53 1.05‐2.23 2.03 1.17‐3.51
Primary location
Body/tail Ref – Ref –
Head 2.41 1.67‐3.47 1.83 1.10‐3.06
Tumor size, cm
<2.0 Ref – Ref –
≥2.0 5.90 3.78‐9.21 4.59 2.57‐8.20
Tumor number
Single Ref – – –
Multiple 0.72 0.35‐1.48 – –
Number of LN examined
1‐7 Ref – Ref –
≥8 3.04 1.99‐4.64 1.61 0.90‐2.90
Tumor differentiation
Well‐differentiated Ref – Ref –
Moderately
differentiated
2.78 1.62‐4.79 1.80 0.85‐3.80
Poorly
differentiated
6.67 2.19‐20.33 0.96 0.10‐9.59
Ki‐67
<3% Ref – Ref –
3%‐20% 3.34 2.11‐5.30 1.83 1.04‐3.22
>20% 7.84 2.97‐20.69 2.28 0.37‐14.03
Abbreviations: CI, confidence interval; LN: lymph node; OR, odds ratio.
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head of pancreas, LNM: 34.5%; tumor size ≥2 cm, LNM: 37.9%; Ki‐
67 > 3%, 39.1% and >8 LN harvested, and LNM: 32.3%) led to a
higher therapeutic index value (Table 3). The reason for the
comparable RFS among these subgroups of patients may be that
LND not only facilitated identification of LNM but also provided an
oncological benefit for patients with seemingly worse characteristics
(and higher LNM rates) by eliminating locoregional disease and
reducing the risk of local recurrence. In addition, data from the
current study demonstrated that an increase in the number of LNs
evaluated was associated with a concomitant increase in the number
of LNM detected. Specifically, removing >8 LNs was associated with a
higher therapeutic index compared with harvesting seven or fewer
LNs (index difference of more than 10), suggesting that eight LNs is
the appropriate goal of LND threshold.24,25
Previous studies have attempted to evaluate the role of LND
in pNET patients to identify subgroups of individuals who might
benefit the most from LND. For example, Harimoto et al22
reported that the presence of LNM was associated with DFS, but
not OS. In turn, these authors recommended that patients with
Ki‐67 ≥ 3% should have routine LND since these patients were at
high risk for locoregional recurrence.22 In a separate study,
Lopez‐Aguiar et al9 noted that less than 10% of patients with a
tumor less than 2 cm had LNM; in addition, patients with a
Ki‐67 < 3% and pNET location in the distal pancreas had
a particularly low risk of LNM (3.4%). In line with these reports,
data from our study suggested that LND could be more mean-
ingful among patients with pNET >2 cm and among patients with
pNET located in the pancreatic head with Ki‐67 > 3%. As such,
surgeons should weigh the potential benefit and related risks
before deciding on the extent of LND. Data from the current
study strongly suggest that routine LND and evaluation of ≥8 LNs
F IGURE 1 Kaplan‐Meier curves demonstrating OS (A) and RFS (B) among patients who underwent LND stratified by the presence of LNM.
LNM, lymph node metastasis; LND, lymph node dissection; OS, overall survival; RFS, recurrence‐free survival [Color figure can be viewed at
wileyonlinelibrary.com]











Overall 0.246 56.0 13.8
Functional status
Nonfunctional 0.259 56.0 14.5 5.8
Functional 0.145 60.0 8.7
Symptomatic
No 0.202 71.1 14.4 0.6
Yes 0.279 49.3 13.8
Primary location
Body/tail 0.179 54.0 9.7
Head 0.345 58.0 20.0 10.3
Tumor size, cm
<2.0 0.094 69.9 6.6
≥2.0 0.379 52.7 20.0 13.4
Tumor number
Single 0.253 53.5 13.5
Multiple 0.196 85.7 16.8 2.7
Grade
Well 0.212 60.2 12.8
Moderate to
poor
0.468 46.0 21.5 8.7
Ki‐67
<3% 0.149 50.1 7.5
≥3% 0.391 51.4 20.1 12.6
Number of LNs harvested
1‐7 0.136 55.1 7.5
≥8 0.323 55.4 17.9 10.4
Abbreviations: LNM, lymph node metastasis; RFS, recurrence‐free
survival.
Bold values represent an index difference of more than 10, which was
considered important.
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should be performed among these patients at high risk of LNM. In
contrast, among patients with a tumor <2 cm (therapeutic index:
6.6), Ki‐67 < 3% (7.5) or pNET located at the pancreatic body or
tail (9.7) the therapeutic benefit of LND appeared to be much
more modest.
Several limitations should be taken into consideration when
interpreting the results of the current study. Due to its retrospective
nature, the current study may be subject to selection bias. In addition,
while the multi‐institutional database may serve to minimize the
interinstitutional bias, the inclusion of multiple centers could have
introduced some bias related to unstandardized surgical operations,
pathological analysis of the surgical specimen, and variation of follow‐
up protocols at individual institutions. In addition, while the cut‐off
value of therapeutic index associated with LND has not been
standardized, the value used in the current study facilitated
comparison to the relative therapeutic value of LND among subgroups
of patients who did or did not have certain characteristics.14
In conclusion, LND was mostly beneficial among patients with
pNETs >2 cm, Ki‐67 ≥ 3%, and lesions located at the pancreatic head
as identification of LNM was most common among individuals with
these tumor characteristics. In addition, evaluation of ≥8 LNs was
associated with a higher likelihood of identifying LNM, as well as a
higher therapeutic index, and therefore this number of nodes should
be considered the goal to evaluate.
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